Company Overview - LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a medical device company focused on products for peripheral vascular disease, which affects over 200 million people globally [2] - The company develops and markets a range of disposable and implantable devices for vascular surgeons, including biologic and biosynthetic grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, and biologic patches for vessel and cardiac repair [2] Financial Performance - In Q2 2025, LeMaitre Vascular reported strong growth, particularly in international sales, with Artegraft sales more than doubling quarter-over-quarter outside the U.S. [3] - Analysts project revenue growth of 13-15%, driven by innovative vascular graft products and increasing international penetration [3] Market Position - The company targets niche vascular device markets valued under $200 million, allowing for steady product development with limited competition [4] - LeMaitre Vascular's surgical devices address critical clinical needs, such as bypassing or replacing diseased arteries and improving dialysis access, maintaining relevance in both clinical and commercial settings [4] Product Highlights - Key products include the Artegraft biologic graft and Valvulotomes, which support advanced vascular surgeries [2][5] - The accelerated adoption of biologic grafts like Artegraft, especially in international markets, highlights the company's momentum in advancing vascular surgery solutions [5]